Since current treatments for both acute and chronic lung diseases are less than ideal, there has been recent interest in the use of cell-based therapies for inflammatory lung disease. Specifically, human amnion epithelial cells (hAECs) have been shown to reduce bleomycin-induced lung injury and prevent subsequent loss of respiratory function, primarily through modulation of the host immune response. The precise mechanisms of this effect remain unclear. We aimed to investigate the potential of hAECs to mitigate bleomycin-induced lung injury in surfactant protein C deficient (Sftpc −/− ) mice, which are highly susceptible to pulmonary injury as a result of impairment of macrophage function. Primary hAECs were administered to wild-type (Sftpc +/+ ) and Sftpc −/− mice 24 h after exposure to bleomycin. Compared to Sftpc +/+ mice receiving bleomycin alone, Sftpc +/+ mice administered hAECs 24 h after bleomycin exposure had decreased expression of proinflammatory genes, decreased macrophage and neutrophil infiltration, fibrosis, collagen content, and α-smooth muscle actin as well as a significant improvement in lung function. Compared to Sftpc −/− mice given bleomycin alone, Sftpc −/− mice administered hAECs 24 h after bleomycin did not have a decrease in inflammatory gene expression or a reduction in macrophage pulmonary infiltration. Subsequently, Sftpc −/− mice did not show any decrease in pulmonary fibrosis or improvement of lung function after hAEC administration. The ability of hAECs to mitigate bleomycin-induced lung injury is abolished in Sftpc −/− mice, suggesting that hAECs require normal host macrophage function to exert their reparative effects.
INTRODUCTION
therapies, including cells derived from the bone marrow, umbilical cord, and placental tissues (24, 35, 36) .
With such a cell therapy in mind, we have recently The World Health Organization predicts that chronic respiratory disorders, such as idiopathic pulmonary shown that human amnion epithelial cells (hAECs) offer promise as a cell therapy for lung disease. Specifically, fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), will become the third most common cause of we have shown that hAECs have the ability to differentiate into lung epithelial-like cells in vitro, expressing thy-death worldwide (44). While the initiating causes of respiratory diseases differ, the resultant lung damage, namely roid transcription factor Nkx2.1 (also known as TTF-1) and pulmonary surfactant proteins A, B, C, and D chronic inflammation, fibrosis, and scarring leading to loss of functional lung tissue, is similar (3, 41, 43) . Cur-(23,31). We have also shown that the administration of hAECs in vivo reduces bleomycin-induced lung inflam-rent therapies for respiratory disease include nonspecific anti-inflammatory agents (8, 11, 17) as well as targeted mation and fibrosis and facilitates the regeneration of normal lung architecture in both immune-compromised anti-inflammatory therapies (9, 37) . Thus far, these therapies have not proven adequate in the long term and are (31) and immune-competent (33) mice. Importantly, these protective and reparative effects are associated often associated with significant side effects. Accordingly, there is an increasingly urgent need for the devel-with mitigation of the loss of lung function induced by bleomycin (33) . However, the precise mechanism(s) by opment of novel, effective treatments of chronic lung disease. With this in mind, there has been recent interest which hAECs exert their effects in this model of lung injury remain uncertain. In particular, it is not clear in the reparative/regenerative potential of cell-based 1478 MURPHY ET AL.
whether hAECs exert their effects via differentiating and fibrosis maximum at day 14 following bleomycin treatment (33) . Body weight, core temperature, and into lung epithelial cells in vivo, as we have shown occurs in immune-compromised mice (31), or whether basal lung function were recorded prior to commencement of experiments and at days 3, 7, and 14. the principle mechanism is via modulation of the host response to injury. Based on a study undertaken in Bleomycin Induction of Pulmonary Fibrosis immune-competent mice where we observed no in vivo differentiation of hAECs and yet mitigation of lung Intranasal administration of bleomycin to rodents is considered a useful model for the histological changes injury, we have recently suggested that the latter is the more likely mechanism (33) . seen in human pulmonary fibrosis (42). Mice were anesthetized with an IP injection of xylazine (2 mg/kg) and To explore the mechanisms of action of hAECs, we undertook the current study to investigate the ability of ketamine (100 mg/kg), allowing administration of an IN dose of bleomycin (4 U/kg for Sftpc −/− mice or 7 U/kg hAECs to both differentiate into lung epithelial cells in vivo and to mitigate bleomycin-induced lung injury in for Sftpc +/+ mice) in a total volume of 24-28 µl saline. The administered doses for each mouse strain were surfactant protein C-deficient (Sftpc −/− ) mice. We chose to undertake the work using this strain for mice for two determined by dose titration to induce comparative levels of pulmonary fibrosis in each strain as determined reasons. First, if we were able to demonstrate the production of surfactant protein C following hAEC admin-by Ashcroft scoring with minimal animal mortality (data not shown). Animals in the saline and hAEC-treated istration then this would confirm that hAECs were differentiating in vivo into functional lung epithelial groups received 21-25 µl IN saline alone. cells. Second, Sftpc −/− mice are known to have a height-hAEC Isolation, Labeling, and Injection ened susceptibility to lung injury secondary to impaired macrophage function, including reduced phagocytic Isolation of hAECs suitable for clinical use was performed as described previously (34) using good manu-activity and increased metalloproteinase activity (18, 19, 26) . This afforded an opportunity to examine one aspect facturing practice (GMP) processes. Prior to IP injection, hAECs were labeled with carboxyfluorescein succinimi-of hAEC-host immune response interaction. dyl ester (CFSE). Briefly, hAECs were resuspended at MATERIALS AND METHODS 15 million cells/ml in 5 µM CFSE and incubated at Animals and Experimental Groups 37°C for 10 min. hAECs were washed three times in PBS and resuspended in sterile saline (10 million cells/ml). All experimental procedures were approved by Monash Medical Centre Animal Ethics Committee and were Lung Function Testing conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Lung function was assessed using unrestrained whole body plethysmography as previously described (29), at Purposes (2006) . Surfactant protein C knockout (Sftpc −/− ) and wild-type (Sftpc +/+ ) mice on a 129/S6 background days 0, 3, 7, and 14 for each group of animals. Briefly, the plethysmograph is a single cylindrical Perspex were sourced from Cincinnati Children's Hospital Medical Center, USA. A total of 61 Sftpc −/− and 69 Sftpc +/+ , chamber (150 × 50 mm) fitted with a temperature and relative humidity probe (Vaisala, Finland) and a volu-6-8-week-old female mice weighing 18-21 g were randomly divided into four treatment groups: Saline-mice metric pressure transducer (Grass Instrument Co., USA). Change in pressure caused by the tidal movement of gas received intranasal instillation (IN) of saline and an intraperitoneal (IP) injection of 400 µl saline 24 h later within the chamber (as the mouse breathes) is measured by the pressure transducer, amplified (Octal Bridge Amp; (Sftpc −/− n = 14, Sftpc +/+ n = 14);bleomycin-mice received IN bleomycin and an IP injection of saline 24 h later Powerlab, AD Instruments, Australia), and recorded (Chart 5.1, AD Instruments, Australia) using a standard (Sftpc −/− n = 14, Sftpc +/+ n = 15);saline + hAECs-mice received IN saline and an IP injection of 4 million desktop PC. The pulmonary function of each mouse was recorded, while the animal was stationary and calm, for hAECs 24 h later (Sftpc −/− n = 16, Sftpc +/+ n = 17);bleomycin + hAECs-mice received IN instillation bleomy-an average of 2 min. Wave form analysis was used to analyze the respiratory trace obtained from each animal, cin and an IP injection of 4 million hAECs 24 h later (Sftpc −/− n = 17, Sftpc +/+ n = 23).
including the measurement of the change in pressure caused by the tidal movement of gas within the chamber All mice were culled at either day 7 (for scoring of inflammation) or day 14 (for scoring of fibrosis) follow-(PT), respiration rate (breaths/min), total breathing cycle time (T tot ; s), inspiration time (T i ; s), and expiration time ing IN bleomycin or saline. These time points for the various analyses were selected based on previous work (T e ; s). Tidal volume (V T ; ml) was calculated as described by Drorbaugh and Fenn (13) . Minute volume that identified that inflammation was maximum at day 7 (V E ; ml/min), inspiratory duty cycle (T i /T tot ; %), inspira-Detection of CFSE-Labeled Cells tory flow rate (V T /T i ; ml/s), and the ratio of inspiration
We used two approaches to detect CFSE-labeled time to expiration time (T i /T e ratio) were also calculated.
hAECs in mouse lungs. First, left and right lung lobes were washed to remove residual blood, minced, and Tissue Collection passed through a 70-µm filter to obtain a single cell sus-Animals were culled by an IP injection of 150 mg/kg pension, and then analyzed using a BD FACSCanto II Lethobarb (Virbac, Australia). The right lung was ligated Flow cytometry system (BD Biosciences, USA). Gates at the right mainstem bronchus, excised, weighed, and were set based on the fluorescent profile of CFSEprocessed for RNA isolation. Upon excising the right labeled and unlabeled hAECs and which excluded dead lung, the trachea was then exposed, cannulated, and the cells as well as small cells such as red blood cells. Secleft lung was instilled with 4% paraformaldehyde (PFA).
ond, to detect CFSE-labeled hAECs histologically, sec-The left lung was then excised, immersed in 4% PFA tions from throughout each left lung were cut and for 48 h, and processed for histology. Flow cytometric incubated with primary antibodies [1:500 rabbit polyanalysis for CFSE-labeled hAECs was performed at day clonal anti-Pro-Surfactant C (ProSP-C), AbCam, USA; 7 on whole lungs (right and left) from six Sftpc −/− and 1:1000 anti-fluorescein, Invitrogen, USA] for 1 h at six Sftpc +/+ (saline + hAECs, n = 2; bleomycin + hAECs, room temperature. Sections were then incubated with n = 4). No other outcomes were collected from these secondary antibody for ProSP-C (AlexaFluor 568 don-12 animals.
key anti-rabbit IgG, Invitrogen, USA) for 1 h at room temperature. Slides were counter stained with DAPI
Assessment of Lung Fibrosis, Collagen, and α-Smooth
(Sigma, USA) and mounted with Dako Fluorescent
Muscle Actin Deposition
Mounting Medium (Dako, Denmark). Slides were visu-Histological sections from throughout each left lung alized with the Leica DMR HCS microscope system to were cut and sequential fields of view (200× magnificadetermine presence of SP-C (red) and CFSE-positive tion) were independently scored, in triplicate, by three cells (green). researchers, each blinded to treatment group, for the Assessment of Lung Inflammation severity of parenchymal fibrosis according to the semiquantitative method previously described by Ashcroft
To assess pro-and anti-inflammatory cytokine responses to bleomycin ± hAECs, we isolated RNA for quantita-(1). An overall mean (±SEM) score was calculated from the triplicate scores from all three scorers. tive PCR. Briefly, total RNA was isolated from snap frozen lungs using TRIzol (Invitrogen) and converted Collagen quantification was performed using Sirius red as previously described (25) . Tissue sections were to cDNA using the Thermoscript Reverse Transcription System (Invitrogen) according to the manufacturer's stained with Sirius red and collagen was quantified by digital image analysis using the Image J software pack-instructions. Quantitative PCR was performed using Lightcycler 480 SYBR Green I Master Mix (Roche, age [National Institutes of Health (NIH)]. For each tissue sample, five images were captured using brightfield Switzerland) and the Corbett Research Rotor-Gene 3000 (QIAGEN, Germany). Primers were directed against light microscopy at 200× magnification using a light microscope (AxioSkop, Zeiss, Germany) with a camera interleukin (IL)-1β, IL-6, macrophage inhibitory factor (MIF), transforming growth factor-β (TGF-β), eosino-attachment (AxioCam ICc 3, Zeiss, Germany). The percentage of area positive for Sirius red was calculated as phil chemotactic factor 1 (also known as Ym1 and chitinase 3-like 3), arginase (Arg1), and 18S. Primer previously described (38) . Each image was converted to a 16-bit black-and-white image and threshold values sequences and annealing temperatures are available upon request. Gene expression of each marker was nor-adjusted to include only stained areas. Threshold values were maintained for all samples. The active area score malized to 18S. We assessed lung inflammation by counting macro-(percentage of stained pixels per field of view) was determined and analyzed using statistical analysis soft-phage and neutrophils in mouse lungs. To do this, we identified macrophages by immunolabeling the F4/80 ware (GraphPad Prism, Graphpad Software Inc., USA). Tissue sections were incubated with primary antibodies antigen and we identified neutrophils with myeloperoxidase. Briefly, tissue sections were incubated with pri-against α-smooth muscle actin (α-SMA) (1:100 ab5694, Abcam, USA) at room temperature for 1 h, followed by mary antibodies against F4/80 (1:100, MCA497R, AbD Serotec, Germany) or myeloperoxidase (1:200, ab45977, incubation with a biotinylated secondary antibody and peroxidase-labeled streptavidin (LSAB+ System HRP, Abcam) at room temperature for 40 min. Tissue sections were then incubated in biotinylated secondary antibody Dako, Denmark). Stained cells were visualized using the liquid DAB substrate with hematoxylin counterstain.
(1:200, AP183β, Chemicon, USA) before detection using the (27) . Briefly, chemotactic assays were per-2A) and Sftpc −/− mice (day 7, 1,905 ± 137 vs. 2,402 ± 130 ml/kg, p ≤ 0.05; day 14, 1,618 ± 81 vs. 2,686 ± 248 formed with 6.5-mm diameter, 3.0-µm pore size, 24well cell culture inserts (BD Biosciences, USA). The ml/kg, p ≤ 0.0001) ( Fig. 2B) , as well as a significantly increased respiratory rate (breaths/min) in both Sftpc +/+ bottom chamber was filled with either 0.2 ml RPMI-1640 or RPMI-1640 containing 600 ng/ml of recombi-(day 14, 287 ± 11 vs. 403 ± 43, p ≤ 0.001) ( Fig. 2C) and Sftpc −/− mice (day 14, 269 ± 10 vs. 378 ± 30, p ≤ 0.001) nant mouse macrophage inflammatory protein (rMIP)-2 (R&D Systems, USA). Macrophages (1 × 10 5 ), with or ( Fig. 2D ). In Sftpc +/+ mice, compared to control animals, bleomycin-treated mice had a significantly increased without hAEC-conditioned medium (CM), were added to the top chamber and plates were incubated at 37°C expiration time (day 3, 0.13 ± 0.01 vs. 0.20 ± 0.01 s, p ≤ 0.0001) ( Fig. 2E ). No significant differences were for 4 h. Cell culture insert membranes were stained with Diff-Quick (Lab Aids, Australia) and the number of observed between Sftpc −/− control and bleomycin-treated groups for expiration time (Fig. 2F ). Compared to con-migrated cells determined using light microscopy.
trol animals, bleomycin-treated mice had a significantly Data Analysis and Statistics decreased inspiration time in both Sftpc +/+ (day 7, 0.1 ± 0.01 vs. 0.07 ± 0.003 s, p ≤ 0.0001) ( Fig. 2G) and Sftpc −/− Data were expressed for each experimental group as mean ± SEM and statistical significance determined using mice (day 7, 0.09 ± 0.003 vs. 0.07 ± 0.01 s, p ≤ 0.0001; day 14, 0.09 ± 0.002 vs. 0.06 ± 0.01 s, p ≤ 0.001) (Fig. 2H ). statistical analysis software (GraphPad Prism, Graphpad
In Sftpc +/+ mice, but not in Sftpc −/− mice, the adminis-shown in Figure 4 . And representative images of Sirius red-stained histological sections are shown in Figure 5 . tration of hAECs following bleomycin was associated with mitigation of impaired lung function. Compared to bleomycin alone animals, administration of hAECs to Analysis of Lung Tissue for hAECs bleomycin-treated Sftpc +/+ mice resulted in a signifi-
We were unable to detect any CFSE labeled cells, by cantly lower minute volume (day 14, 2,891 ± 443 vs.
either flow cytometry or immunohistochemistry, in any of 2,034 ± 80.4 ml/kg, p ≤ 0.05) ( Fig. 2A) , lower respiraour groups of animals. A sample of CFSE-labeled cells tion rate (breaths/min) (day 14, 403 ± 43 vs. 310 ± 10, utilized as a positive control retained the CFSE label and p ≤ 0.001) (Fig. 2C ), lower expiration time (day 3, 0.20
were viable for the duration of the experiment. Surfactant ± 0.01 vs. 0.17 ± 0.01 s, p ≤ 0.05) ( Fig. 2E) , and a protein C expression was only detected in the endogenous longer inspiration time (day 7, 0.07 ± 0.01 vs. 0.08 ± lung epithelium of Sftpc +/+ mice (data not shown). 0.01 s, p ≤ 0.05) (Fig. 2G) 6) and Sftpc −/− tion of alveolar spaces followed by the deposition of a mice (IL-1β: 0.4 ± 0.3 vs. 1.8 ± 0.5, p ≤ 0.05; IL-6: matrix of fibronectin, collagen, and α-smooth muscle 0.70 ± 0.2 vs. 8.5 ± 4, p ≤ 0.05; TGF-β: 1.6 ± 0.3 vs. actin, a product of activated myofibroblasts (41) . Com-8.6 ± 1.5, p ≤ 0.05) (Fig. 6 ). There was no effect of bleopared to saline-treated controls, pulmonary fibrosis at mycin on MIF expression in Sftpc −/− mice (Fig. 6 ). day 14, as assessed by Ashcroft scoring, was increased
The administration of hAECs to bleomycin-treated by bleomycin treatment in both Sftpc +/+ (0.8 ± 0.1 vs.
Sftpc +/+ mice was associated with significantly lower 5.0 ± 0.3, p ≤ 0.0001) ( Fig. 3A) and Sftpc −/− mice (0.8 ± proinflammatory pulmonary gene expression than in 0.1 vs. 4.2 ± 0.6, p ≤ 0.0001) (Fig. 3B ). The extent of bleomycin-alone animals (IL-1β: 4 ± 2.3 vs. 52.2 ± fibrosis induced in Sftpc +/+ and Sftpc −/− mice was similar, 29.6, p ≤ 0.05; IL-6: 7.4 ± 2.1 vs. 20.7 ± 7.6, p ≤ 0.05; as expected from the dose-titration studies. Administra-MIF: 5.5 ± 1.9 vs. 13.2 ± 3.5, p ≤ 0.05; TGF-β: 3.3 ± tion of hAECs after bleomycin treatment significantly 0.7 vs. 8 ± 2.3, p ≤ 0.05) (Fig. 6 ). In contrast, in Sftpc −/− reduced fibrosis in Sftpc +/+ mice (5 ± 0.3 vs. 3.5 ± 0.4, animals the administration of hAECs 24 h after bleomyp ≤ 0.05) ( Fig. 3A) but not in Sftpc −/− mice (4.2 ± 0.6 vs.
cin was associated with significantly lower pulmonary 5.1 ± 0.6, p = 0.34) ( Fig. 3B) . gene expression only for IL-1β (0.5 ± 0.3 vs. 1.8 ± 0.5, Compared to control animals, bleomycin administrap ≤ 0.05) and TGF-β (0.6 ± 0.1 vs. 8.6 ± 1.5, p ≤ 0.05) tion increased collagen content at day 14 in both Sftpc +/+ (Fig. 6 ). (2.54 ± 0.45% vs. 15.13p ≤ 2.58%, p ≤ 0.0001) ( Fig.  3C) and Sftpc −/− mice (1.70 ± 0.15% vs. 9.06 ± 1.44%, Effect of Bleomycin and hAEC Administration p ≤ 0.0001) (Fig. 3D ). In the Sftpc +/+ mice, this effect of on Leukocyte Number bleomycin was significantly mitigated by hAEC administration (15.13 ± 2.58% vs. 9.11 ± 1.22%, p ≤ 0.05)
Changes to the leukocyte number in the lung were determined on day 7 in order to evaluate hAEC-medi- (Fig. 3C) , an effect not observed in the Sftpc −/− mice (9.06 ± 1.44% vs. 9.38 ± 1.32%, p = 0.88) ( Fig. 3D) .
ated effects at a time where maximal inflammation would be observed in the bleomycin model. Compared Similarly, compared to control animals, bleomycin administration increased day 14 levels of α-SMA in to control animals, in both Sftpc +/+ mice and Sftpc −/− mice bleomycin administration was associated with an both Sftpc +/+ (76 ± 24-fold change compared to control, p ≤ 0.01) ( Fig. 3E) and Sftpc −/− mice (84 ± 21-fold change increased number of both lung macrophages [Sftpc +/+ : 28.8 ± 4.4-fold change compared to control, p ≤ 0.0001 compared to control, p ≤ 0.05) (Fig. 3F ). While the administration of hAECs following bleomcyin mitigated (Fig. 7A) ; Sftpc −/− : 24.8 ± 9.1-fold change compared to control, p ≤ 0.05 (Fig. 7B) ] and neutrophils [Sftpc +/+ : increases in pulmonary α-SMA in Sftpc +/+ mice (21 ± 9fold change compared to control, p ≤ 0.05) (Fig. 3E) , 44.4 ± 11.3-fold change compared to control, p < 0.0001 (Fig. 7C) ; Sftpc −/− : 31.3 ± 8.5-fold change compared to this effect was not in seen in Sftpc −/− mice (day 14, 71.99 ± 25.20-fold change compared to control) (Fig. 3F) .
control, p ≤ 0.0001 (Fig. 7D) ]. In Sftpc +/+ mice, administration of hAECs to bleomycin-treated animals partially Representative images of histological sections are mitigated the bleomycin-induced increase in both macrophages and neutrophils (macrophages: 10.80 ± 4.496fold change compared to control, p ≤ 0.001; neutrophils: 13.6 ± 4.6-fold change compared to control, p ≤ 0.001). However, while the administration of hAECs to bleomycin-treated Sftpc −/− mice partially mitigated the neutrophil influx (14.3 ± 3.3-fold change compared to control, p ≤ 0.001), there was no significant effect on macrophage number (26 ± 5.8-fold change compared to control).
Gene expression for Ym1 and arginase-1, markers of the alternatively activated macrophage phenotype, was measured at day 7. Compared to control Sftpc +/+ mice, bleomycin significantly increased gene expression of Ym1 (8.53 × 10 −6 ± 8.40 × 10 −6 vs. 269.6 ± 140.4, p ≤ 0.001) and arginase-1 (0.081 ± 0.045 vs. 31,709 ± 14,215, p ≤ 0.05). Compared to bleomycin-treated Sftpc +/+ mice, mice receiving hAECs 24 h after bleomcyin had further increased gene expression for Ym1 (269.6 ± 140.4 vs. 1,895 ± 406.1, p ≤ 0.001) and arginase-1 (31,709 ± 14,215 vs. 1.11 × 10 6 ± 0.556 × 10 6 , p < 0.05). No significant differences were observed for Arg1 or Ym1 gene expression between Sftpc −/− groups (Fig. 8) .
Effect of hAEC Supernatant on Macrophage Migration In Vitro
An in vitro chemotactic migration assay was used to determine the effect of hAEC conditioned medium (CM) on the migration of macrophages from Sftpc +/+ and Sftpc −/− mice. A macrophage cell line derived from C57Bl6 bone marrow used as a positive control migrated towards the MIP-2 chemotactic gradient (9.0 ± 0.7-fold change compared to control, p ≤ 0.001). Migration was significantly inhibited by the addition of hAEC CM (1.1 ± 0.7-fold change compared to control, p ≤ 0.001). Macrophages from Sftpc +/+ mice also migrated towards the MIP-2 chemotactic gradient (4.7 ± 0.6-fold change compared to control, p ≤ 0.01) and migration was significantly inhibited by the addition of hAEC CM (1.7 ± 0.4-fold change compared to control, p ≤ 0.05) ( Fig. 9 ). Macrophages from Sftpc −/− mice did not have a significant increase in In this study we investigated the ability of hAECs to ≤ 0.05, **p ≤ 0.001. mitigate acute bleomycin-induced lung injury by both differentiation into lung epithelial cells in vivo and by modulation of host lung inflammation and subsequent structural and functional lung changes. We demonstrated that administration of hAECs reduced bleomycininduced injury, both inflammation and fibrosis, and loss and has a lower level of sensitivity compared to other techniques (33) , in this study we utilized both FACS We were unable to demonstrate any integration or differentiation of hAECs into the lungs of either mouse analysis and immunohistochemistry to identify CFSElabeled cells in host tissue. As before, we were unable strain. Instead, the ability of hAEC therapy to mitigate lung injury appeared related to effects on macrophage to detect any hAECs in either the injured or uninjured lung. In light of our inability to show either integration recruitment and polarization.
We and others have shown that placental and or differentiation of hAECs in immune competent mice, and yet still show mitigation of bleomycin injury by amnion-derived cells are effective in mitigating and repairing bleomycin-induced lung injury (5, 31, 33) .
hAEC administration, we believe that differentiation of hAECs into lung epithelial cells is not likely to be the However, precisely how hAECs exert these effects remains uncertain. While studies in immune compro-key mechanism underlying the prevention and/or repair of acute lung injury. Rather, we suggest that the hAECs mised mice have shown that both hAECs (31) and amniotic fluid-derived cells (6) are able to integrate into the primarily exert their effects by reducing acute inflammation, both leukocyte infiltration and cytokine responses, host epithelium and differentiate in vivo into lung epithelial cells following bleomycin lung injury (6), we and thereby mitigating subsequent pulmonary fibrosis. A wide array of inflammatory and fibrotic signaling have not been able to show this in immune competent mice in either a previous study (33) or in this current pathways are activated by bleomycin, including key players in lung injury such as TGF-β (2), the inflamma-study. Acknowledging that FACS analysis, one of the approaches we use for cell detection, excludes dead cells some (12, 30, 46) , and inflammatory cytokines such as IL-1β, IL-6, interferon-γ (IFN-γ), and tumor necrosis and Sftpc −/− mice may involve the recruitment of macrophages to the site of injury. In this regard, impaired mac-factor-α (TNF-α) (39) . In this regard, hAEC administration has been shown to significantly decrease profibrotic rophage function (altered morphology, reduced phagocytic activity, and increased metalloproteinase activity) in Sftpc −/− gene expression in bleomycin-treated mice (33), a finding confirmed in the current study where TGF-β gene mice is thought to underlie this strain's increased susceptibility to respiratory tract infections and, we suggest, expression was significantly reduced following hAEC administration in both Sftpc +/+ and Sftpc −/− mice. We also underlie heightened and prolonged fibrosis following bleomycin insult (18) (19) (20) 26) . noted that while hAEC administration significantly reduced IL-1β expression in both Sftpc +/+ and Sftpc −/− Specifically, Sftpc −/− macrophages express markers of alternative activation, such as increased arginase activ-mice, the relative expression of IL-1β in bleomycintreated Sftpc +/+ mice was 30-fold greater than in Sftpc −/− ity, which contribute to matrix remodeling and collagen synthesis (15, 22) , as well as abundant expression of mice. This suggests that the IL-1β response to bleomycin in Sftpc −/− mice is compromised. Further, hAEC chitinase protein Ym1, which has been associated with epithelial inflammation and asthma (7, 14) . Further, pro-administration significantly reduced IL-6 and MIF gene expression in Sftpc +/+ mice, an effect that was not duction of matrix metalloproteinases 2 and 9 are increased in alveolar macrophages of Sftpc −/− mice, indi-observed in Sftpc −/− mice. As IL-6 and MIF are involved in the recruitment of macrophages into the lung follow-cating that macrophages in these mice may have an altered role in the process of inflammation and the ing bleomycin injury (40) , these data suggest that one difference in the effect of hAEC administration in Sftpc +/+ development of fibrosis (18) . IL-10 (21,32) to aid in the resolution of inflammation and wound healing. IL-4 and IL-13 also augment expression of IL-1 decoy receptor and the IL-1 receptor α-chain in vitro and in vivo, counteracting the proinflammatory actions of IL-1 (16, 28) . A recent paper by Zhang and colleagues reported that human gingival mesenchymal stem cells (MSCs) aided repair in a murine model of cutaneous wound healing (47) by encouraging the polarization of macrophages to the alternatively activated phenotype. Taken together with the results from the current study, we believe that macrophages derived from Sftpc +/+ mice but did not alter migration of macrophages from Sftpc −/− mice supports REFERENCES our suggestion that hAECs exert their protective effects via macrophage modulation. Further, in wild-type mice
